Loading...
Illumina, a leading genomics company, is expected to receive an order from the European Union (EU) on Thursday to divest Grail, a cancer test maker. This decision comes as Illumina faces the possibility of losing a court appeal in the US or EU. The EU antitrust regulators have formally ordered Illumina to sell Grail, as the EU escalates its legal battle over the acquisition. Illumina has stated that it will decide whether to integrate or divest Grail only if it wins both pending cases. In a separate development, European regulators are considering an appeal from Amylyx Pharmaceuticals, which initially received a negative recommendation for its ALS treatment.
Illumina was formally ordered to undo its $7 billion acquisition of cancer-test provider Grail as the EU ramped up a legal fight over a deal the firms completed without its permission https://t.co/HPVpwBPOJ2
Illumina ordered by EU antitrust regulators to sell Grail https://t.co/GlM5fxVKbg https://t.co/nHnhqK9WyM
Illumina to divest cancer test maker Grail if it loses US or EU court appeal https://t.co/IRVFzFXrbz https://t.co/Fr8JCkHF5f
$ILMN "will decide outcome of whether to integrate or divest part or all of Grail only if we win both pending cases" - REUTERS https://t.co/EVGhwwxskE
$ILMN "will decide outcome of whether to integrate or divest part or all of Grail only if we win both pending cases" - REUTERS
European regulators are considering an appeal from Amylyx Pharmaceuticals after initially recommending against approving the company’s #ALS treatment. https://t.co/VWCa2QQIir
Illumina to get EU order on Thursday to divest Grail, source says https://t.co/VVrCBkhXJu https://t.co/6HWRlsxARA